HUMAN TRIALS
Clinical Trials: Human NF-1 Trial
A first in man clinical vaccine trial is under development, currently in discovery phase. Serum samples from pediatric patients diagnosed NF-1 brain cancer have been collected. These samples will be queried on our chips for optimal REDN components to include in a therapeutic vaccine for NF-1 prediatric brain cancer.
Clinical Trials: Human RMC Trial
Another human vaccine trial is in discovery phase. Serum samples from patients diagnosed with renal medullary cancer (RMC) are being collected. These samples will be queried on our chips for optimal REDN components to include in a therapeutic vaccine for early-stage HSA.
CANINE TRIALS
Clinical Trials: Canine Preventative Cancer (VACCS) Trial
VACCS is the world’s largest canine cancer vaccine study ever done; it will test the efficacy of a preventative vaccine against cancer.
We have shown REDNs are strong immunogens and have anti-tumor effects as vaccines in mouse models (Shen et. al. Sci. Rep. 2019). Based on these preclinical studies, we designed a REDN vaccine to prevent cancer in dogs and initiated a research trial in 2019 with 800+ owner-enrolled dogs. Safety review boards have found no side-effects. Its fifth year will be completed Spring 2024.
Clinical Trials: Canine HSA Trial
Another canine vaccine trial is in discovery phase. Serum samples from dogs diagnosed with early stage Hemangiosarcoma (HSA) have been collected. These samples are being queried on our chips for optimal REDN components to include in a therapeutic vaccine for early stage HSA.
